Barclays Reaffirms Their Hold Rating on SKF AB (0NWX)
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
According to TipRanks, Lee, CFA is a 2-star analyst with an average return of 0.5% and a 44.74% success rate. Lee, CFA covers the Industrials sector, focusing on stocks such as Jungheinrich, KION GROUP AG, and SKF AB.
Currently, the analyst consensus on SKF AB is a Moderate Buy with an average price target of SEK220.00.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Fundstrat's Tom Lee: Owning Bitcoin Is Like Owning Land Under A McDonald's
Bitcoin (CRYPTO: BTC) is undergoing a reframing in how institutions may treat it, not as a volatile asset, but as digital infrastructure akin to real estate. What Happened: Fundstrat co-founder and Bitmine (AMEX:BMNR) chairman Tom Lee drew a sharp analogy in an conversation with Bitwise, saying Bitcoin as a treasury asset is like owning the land underneath a McDonald's franchise, not running the business. "It's better to be the landowner of a McDonald's franchise than the operator," Lee said, explaining that corporations may begin viewing Bitcoin as a foundational asset — one that provides long-term capital leverage much like commercial real estate does in traditional business models. This shift, according to Lee, is a structural rethinking of how companies manage their treasuries. Traditionally, firms preferred renting space or outsourcing infrastructure, similar to how telecoms once undervalued the ownership of cell towers. But just as telecom towers grew into stand-alone, multi-billion dollar businesses, Lee sees Bitcoin following the same path—as infrastructure with compounding network value. Also Read: Why It Matters: Lee further elaborated on this thesis in an interview with CNBC, where he remained bullish on both equity markets and digital assets despite short-term market consolidation. Lee noted that the recent pullback in equities was a consolidation phase, predicting the S&P 500 could return to its all-time highs around 6,500–6,600 in the coming weeks, and reach 7,000 within the next 12 months. As chairman of Bitmine, a newly emerging ETH (CRYPTO: ETH)-focused public company, Lee noted that Bitmine now holds nearly $3 billion in Ether, making it the largest ETH treasury in the world and third-largest overall in crypto. The company recently secured investment from legendary investor Bill Miller, further signaling institutional confidence in long-term crypto plays. Lee argued that weakening labor data and cooling inflation could prompt a dovish pivot by the Fed this fall, potentially igniting a broader market rally that benefits both equities and digital assets. Read Next: Image: Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article Fundstrat's Tom Lee: Owning Bitcoin Is Like Owning Land Under A McDonald's originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Miami Herald
2 hours ago
- Miami Herald
Stock Market Today: Algorithms Are Not Efficient
I began my career not in journalism but on the New York Stock Exchange. Technically, I wasn't on the floor, but I worked 16 stories above it, trading through a network of brokers who were on the floor. I was there in trading activity, if not in body. It probably shows in my writing. Back in those days some 1,300 traders plus support staff made up the crowds where stocks were traded and prices were discovered. It was a loud and active place, where price efficiency ruled. Today, the NYSE floor is an empty place. Market makers still work there, but price discovery happens largely through computers. This is what the floor looks like today: Jason Meshnick In today's Market Recon piece over on TheStreet Pro, Stephen "Sarge" Guilfoyle discusses the trading action from Friday and Monday, and tells us that both Friday and Monday were overshoots from where the market should have traded. He says: "On Monday, U.S. equity markets absolutely roared back from a harsh selloff on Friday. On Friday, the algorithms that run price discovery in 2025 sold stocks en masse because of a recessionary looking labor report that was really three consecutive recessionary-looking labor reports at once. On Monday, those same algorithms bought the market hand over fist because now the Fed will likely have to cut short-term interest rates in six weeks." He goes on to say that this game of "Chutes and Ladders" is occurring because we've removed humans from the art of price discovery and replaced them with algorithms. While the market is much cheaper to run (spreads are down), markets are less efficient. In other words, day-to-day volatility might be lower, but reaction to news is much harsher. I couldn't agree more. Sarge also tells us that Wall Street strategists have turned bearish. They see a lethal combination of softening economic data and sky-high valuations. Perhaps "lethal" is a strong word. More accurately, they see a dip on the horizon that they feel will be worth buying. But the reason why I'm quoting Sarge so much today is that he more succinctly than anybody has listed the four reasons that valuations are high and deserve to be. Lower taxesLess regulationExpected lower interest ratesIncreased productivity (on a per-employee basis) driven by artificial intelligence. It all comes down to potential corporate growth and reduced expenses. Demand for workers probably will drop, however, which could be a net negative for economic growth. How is the stock market looking this morning? Slightly up. S&P 500 futures are higher by 0.12%, while Nasdaq futures are up 0.27%. ThinkOrSwim It's still earnings season and several major companies have reported this morning. TipRanks After market close, we await reports from AMD, Super Micro Computer, and others, including EV makers Rivian and Lucid. TipRanks Check back throughout the day! The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc.
Yahoo
3 hours ago
- Yahoo
Annual spending on specialty drugs continues to increase but at a slower pace than prior years, driven in part by biosimilar adoption.
DALLAS, August 05, 2025--(BUSINESS WIRE)--Pharmaceutical Strategies Group ("PSG"), an EPIC company, released the Artemetrx State of Specialty Spend and Trend report. This annual report provides a comprehensive analysis based on real world data of utilization of specialty medications across both pharmacy and medical benefits. This year's report revealed per member per year specialty drug cost increased from $1,333 in 2023 to $1,641 in 2024. However, specialty drug trend decreased to 9.6% in 2024 on a gross cost basis, a decline from 14.4% in 2023. Notably, cost per claim was meaningfully less of a contributor to trend this year versus recent years. "The data reveals a compelling story regarding what is happening with specialty drugs. Overall costs continue to increase for healthcare payers, but what is driving that cost is changing," stated Morgan Lee, PhD, Senior Director of Research & Strategy at PSG. "Adoption of Humira biosimilars helped pull specialty trend down this year, which is evident throughout the report," Lee added. While Humira continued its multi-year reign as the top specialty drug in terms of overall spend, this popular drug experienced negative utilization and cost per claim trends driven by the adoption of biosimilars. "In 2024, we saw the benefit to healthcare payers of Humira biosimilars as PBMs shifted strategies to take advantage of competition in the market," observed Renee Rayburg, RPh, Vice President of Clinical Strategy at PSG. "We expect to see faster adoption of Stelara biosimilars, which entered the market early this year. However, we're also seeing a push to move patients from these drugs to other brand drugs that do not have biosimilar competition." The Artemetrx State of Specialty Spend and Trend Report reflects PSG's commitment to providing data-driven insights regarding the management of and opportunities to optimize specialty medications. The complimentary report can be downloaded here. Additional findings covered in the report include: The percentage of members utilizing a specialty drug increased (4.7%), while average specialty claims per utilizer was steady (5.9) The shift of specialty drug spending to the pharmacy benefit continued The top three categories for specialty drug spend remained unchanged: Inflammatory Disorder, Oncology, Multiple Sclerosis PSG will host a webinar on August 13th, at 1:00 ET to discuss how this report can shape a roadmap for proactive specialty spend control. Registration is available online. About Pharmaceutical Strategies Group (PSG) Pharmaceutical Strategies Group, an EPIC company, relentlessly advocates for clients as they navigate complex and ever-changing drug cost management challenges. PSG is an independent consultant, empowering healthcare payers to optimize their pharmacy program. As a strategic partner, PSG helps clients by providing industry-leading intelligence and technologies to realize billions of dollars in drug cost savings for clients every year. About Artemetrx® Artemetrx is a proprietary SaaS platform developed by Pharmaceutical Strategies Group, an EPIC company. As a revolutionary technology solution integrating pharmacy and medical claims data for specialty drug cost management, Artemetrx provides market-leading specialty drug insights to payers. It delivers unparalleled intelligence and line-of-sight into serious challenges perpetuating out-of-control drug costs and compromised patient outcomes. PSG's innovative drug management solutions, including Artemetrx, deliver actionable insights with exceptional financial and clinical value. PSG functions as a strategic partner through industry-leading intelligence and technologies to realize billions of dollars in drug cost savings for clients every year. View source version on Contacts Artemetrx Business Development Travis Media Contact Gregory FCA For Pharmaceutical Strategies GroupKara Lesterepic@ Sign in to access your portfolio
